Royal Bank of Canada’s Novartis NVS Stock Holding History

Royal Bank of Canada’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-37,100	Closed	-$4.27M	–	7134
2024 Q3	$4.27M	Buy	+37,100	New	+$4.21M	﹤0.01%	2404
2023 Q3	–	Sell	-138,000	Closed	-$13.9M	–	7414
2023 Q2	$13.9M	Buy	+138,000	New	+$13.8M	﹤0.01%	1365
2017 Q4	–	Sell	-19,307	Closed	-$1.49M	–	6773
2017 Q3	$1.49M	Buy	+19,307	New	+$1.46M	﹤0.01%	2903

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada's NVS Position: Q1 2026 in Review

Royal Bank of Canada increased its Novartis (NVS) stake by 7.1% in Q1 2026, buying an estimated $6.25M and bringing the position to 618,710 shares worth $94.5M. The position accounts for 0.02% of the portfolio, ranked #650.

Royal Bank of Canada first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $146M in Q1 2019. 1,598 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

Royal Bank of Canada held 618,710 shares of Novartis worth $94.5M as of Q1 2026.
Royal Bank of Canada bought 40,788 Novartis shares in Q1 2026, an estimated $6.25M.
Novartis made up 0.02% of Royal Bank of Canada's portfolio in Q1 2026, its #650 holding.
Royal Bank of Canada first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
Royal Bank of Canada's Novartis position peaked at $146M in Q1 2019.
1,598 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.